ADReCS

Pharmaceutical Information

Drug Name	Carboplatin
Drug ID	BADD_D00364
Description	Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage	Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status	approved
ATC Code	L01XA02
DrugBank ID	DB00958
KEGG ID	D01363
MeSH ID	D016190
PubChem ID	426756
TTD Drug ID	D0X7HM
NDC Product Code	0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII	BG3F62OND5
Synonyms	Carboplatin \| cis-Diammine(cyclobutanedicarboxylato)platinum II \| CBDCA \| Paraplatin \| Paraplatine \| Platinwas \| Ribocarbo \| Carboplat \| Neocarbo \| Carbosin \| Carbotec \| Ercar \| JM-8 \| JM 8 \| JM8 \| Nealorin \| NSC-241240 \| NSC 241240 \| NSC241240 \| Blastocarb

Chemical Information

Molecular Formula	C6H12N2O4Pt
CAS Registry Number	41575-94-4
SMILES	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Bronchial fistula	22.03.02.011	0.000168%
Epiglottic oedema	22.04.02.006	0.000168%		Not Available
IgA nephropathy	20.05.01.016; 10.02.01.063	0.000224%		Not Available
Lymphadenopathy mediastinal	22.09.03.006; 01.09.01.025	0.000112%		Not Available
Malignant pleural effusion	22.05.04.001; 16.32.03.014	0.000112%		Not Available
Metastases to bone	16.22.02.005; 15.09.03.006	0.000672%		Not Available
Metastases to lymph nodes	01.09.01.015; 16.22.02.006	0.000168%		Not Available
Mixed deafness	17.04.07.006; 04.02.01.014	0.000168%		Not Available
Pancreatic carcinoma metastatic	16.13.10.003; 07.21.09.006	0.000168%		Not Available
Recurrent cancer	16.16.01.015	0.000168%		Not Available
Seminoma	21.13.02.004; 16.25.03.002	0.000112%		Not Available
Pericardial effusion malignant	16.32.03.026; 02.06.01.009	0.000112%		Not Available
Metastases to meninges	17.02.10.012; 16.22.02.003	0.000168%		Not Available
Pulmonary cavitation	22.01.02.022	0.000168%		Not Available
Laryngeal discomfort	22.12.03.009	0.000112%		Not Available
Thyroid cancer metastatic	16.24.03.006; 05.02.05.009	0.000112%		Not Available
Breast cancer metastatic	21.05.01.016; 16.10.01.008	0.000168%		Not Available
Growth hormone deficiency	05.03.02.004	0.000280%		Not Available
Abdominal compartment syndrome	24.04.09.009; 07.11.01.017	0.000224%		Not Available
Gastrointestinal erosion	07.04.04.009	0.000392%		Not Available
Hormone-refractory prostate cancer	21.04.02.007; 16.25.01.004	0.000168%		Not Available
Portal venous gas	07.01.06.033	0.000224%		Not Available
Iris neovascularisation	24.03.07.012; 06.07.06.001	0.000224%		Not Available
Astrocytoma, low grade	17.18.04.001; 16.09.04.001	0.000280%		Not Available
Stress cardiomyopathy	24.04.04.026; 02.04.01.012	0.000112%		Not Available
Vasogenic cerebral oedema	17.07.02.008	0.000112%		Not Available
Butterfly rash	15.06.02.010; 10.04.03.010; 23.03.13.019	0.000224%		Not Available
Respiratory fatigue	22.02.01.042	0.000224%		Not Available
Band sensation	17.16.01.004	0.000280%		Not Available
Psychological trauma	19.01.02.017	0.002127%		Not Available

The 19th Page First Pre 19 20 21 Next Last Total 21 Pages